Abstract:Objective:To explore the effect of astragalus polysaccharide (APS) on fatty acid metabolism and lipid toxicity in diabetic cardiomyopathy.Methods:The 5 weeks old male type 2 diabetes model db/db mice were divided into astragalus polysaccharides group,metformin group and diabetic group,according to the random number table method.Each group had 8 rats,which were given APS 2000 mg/kg,metformin 2000 mg/kg and an equal amount of saline through nasogastric tube for 12 weeks respectively.Eight same-age C57BL/6J mice were set as normal group and fed with the same amount of normal saline.Cardiac function was examined by echocardiography in each group.Bligh-Dyer and ESIMS were used to detect myocardial triglyceride deposition.Micro-positron emission tomography was used to detect myocardial fatty acid uptake and index of oxidative metabolism.Western blot was used to detect the protein expression level of key enzymes involved in the metabolism of fatty acids.Results:(1) The LVEDD and LVESD were increased significantly,while the LV fractional shortening (FS) were decreased significantly in diabetic group compared with those in normal group (all P＜0.05).The above indexes of APS group were significantly improved compared with those of diabetic group (all P＜0.05).There was no significant difference in above indexes between metformin group and diabetic group.(2) Compared with the normal group,the fatty acid uptake rate,the free fatty acid oxidation rate,the triglyceride content and the triglyceride subtypes in diabetic group were significantly increased (all P＜0.05) The above indexes in APS group were significantly lower than those in diabetic group (all P＜0.05).There was no significant difference in above indexes between the metformin group and diabetic group.(3) Compared with normal group,the protein expression levels of PPARα,M-CPT 1 and ACO in myocardium were significantly increased in diabetic group (all P＜0.05).The expression of these proteins was significantly lower in APS group than those in diabetic group (all P＜0.05).There was no significant difference in protein expression between the metformin group and diabetic group.Conclusions:APS can improve fatty acid metabolism in diabetic myocardium,including improving cardiac function,decreasing fatty acid uptake and utilization rate,free fatty acid oxidation rate and triglyceride content in the myocardium of diabetic mice,and controlling the fatty acid metabolism related proteins in the myocardium of diabetic mice at normal levels.

Astragalus polysaccharide liposome nanoparticles mediate fatty acid translocase (FAT)/CD36 to improve fatty acid metabolism and regulate glucocorticoid receptor levels in diabetic cardiomyopathy

Combined Treatment with Ultrasound-Targeted Microbubble Destruction Technique and NM-aFGF-loaded PEG-nanoliposomes Protects Against Diabetic Cardiomyopathy-Induced Oxidative Stress by Activating the AKT/GSK-3β1/Nrf-2 Pathway

The Critical Role Of Astragalus Polysaccharides For The Improvement Of Ppra Alpha-Mediated Lipotoxicity In Diabetic Cardiomyopathy

Mechanism of astragalus polysaccharide therapy in improving myocardial lipid toxicity in db/db diabetic obese mice

Prevent Diabetic Cardiomyopathy in Diabetic Rats by Combined Therapy of Afgf-Loaded Nanoparticles and Ultrasound-Targeted Microbubble Destruction Technique.

Astragalus polysaccharides repress myocardial lipotoxicity in a PPARalpha-dependent manner in vitro and in vivo in mice

Therapy With Astragalus Polysaccharides Rescues Lipotoxic Cardiomyopathy In Mhc-Ppar Alpha Mice

Therapy with Astragalus polysaccharides rescues lipotoxic cardiomyopathy in MHC-PPARα mice

Astragalus polysaccharide prevents heart failure-induced cachexia by alleviating excessive adipose expenditure in white and brown adipose tissue

Effect of Astragalus Polysaccharides on Cardiac Dysfunction in Db/db Mice with Respect to Oxidant Stress

Effects of APS Activates Hepatic Insulin Signaling in HFD-induced IR Mice.

Improvement of Myocardial Glycolipid Metabolic Disorder in Diabetic Hamster with Astragalus Polysaccharides Treatment

Astragalus polysaccharides alleviates cardiac hypertrophy in diabetic cardiomyopathy via inhibiting the BMP10-mediated signaling pathway

The effect of Astragalus polysaccharides on attenuation of diabetic cardiomyopathy through inhibiting the extrinsic and intrinsic apoptotic pathways in high glucose -stimulated H9C2 cells

Astragalus polysaccharides inhibit oxidation in high glucose-challenged or SOD2-silenced H9C2 cells.

Pharmacological Effects and Molecular Protective Mechanisms of Astragalus Polysaccharides on Nonalcoholic Fatty Liver Disease

Astragalus polysaccharides affect insulin resistance by regulating the hepatic SIRT1-PGC-1α/PPARα-FGF21 signaling pathway in male Sprague Dawley rats undergoing catch-up growth

Astraglus polysaccharide attenuates nonalcoholic fatty liver disease through THDCA in high-fat diet-fed mice

Astragalus polysaccharides inhibited diabetic cardiomyopathy in hamsters depending on suppression of heart chymase activation

Astragalus polysaccharides improve cardiomyopathy in STZ-induced diabetic mice and heterozygous (SOD2+/-) knockout mice.

Integrated Metagenomic and Metabolomic Analyses of the Effect of Astragalus Polysaccharides on Alleviating High-Fat Diet–Induced Metabolic Disorders